Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508683 | 0.78 | PTGDR2 (0.46) | PTGDR2MAPTKCNH2 | |
| SCHEMBL508730 | 0.76 | PTGDR2 (0.37) | PTGDR2MAPTKCNH2 | |
| SCHEMBL5224587 | 0.75 | KCNH2 (0.40) | PTGDR2MAPTKCNH2KDM4ERARG | |
| SCHEMBL508289 | 0.75 | PTGDR2 (0.41) | PTGDR2MAPTKCNH2CARM1PRMT6 | |
| SCHEMBL10250143 | 0.74 | PTGDR2 (0.40) | PTGDR2MAPTKCNH2KDM4EALDH1A1 | |
| SCHEMBL5228559 | 0.73 | KEAP1 (0.37) | PTGDR2MAPTCARM1PRMT6PPARG | |
| SCHEMBL509302 | 0.73 | PTGDR2 (0.38) | PTGDR2MAPTKCNH2ALDH1A1 | |
| SCHEMBL509492 | 0.72 | ALDH1A1 (0.40) | PTGDR2MAPTKCNH2CARM1PRMT6 | |
| SCHEMBL5226712 | 0.71 | KCNH2 (0.38) | PTGDR2MAPTKCNH2 | |
| SCHEMBL508772 | 0.70 | MAPT (0.41) | PTGDR2MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | RRM2B, REV1, RRM2 | PTGDR2 3222/4885MAPT 2220/4885KCNH2 3441/4885 |
| US-20120029192-A1 | Pyrazole Derivatives | POLRMT, PDCD11, DPYD | PTGDR2 3632/4885MAPT 1474/4885KCNH2 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.